A number of cardiac interventional procedures are available for the treatment of angina, including percutaneous transluminal coronary angioplasty (PTCA), stent insertion and rotational atherectomy (RA). Variable degrees of myocardial cell injury during PTCA and stent insertion have been observed, based on rises in creatine kinase MB isoenzyme (CK-MB) and cardiac troponin T (cTnT) 6±24 h post-procedure. As there are many variations in technique within each procedure it would be helpful to be able to determine objectively the degree of myocardial damage in order to optimize technique. We measured CK-MB, cTnT and cardiac troponin I (cTnI) to ascertain which is the most sensitive marker for minor myocardial damage in this setting. Blood samples were taken both before and 6, 14 and 24 h after the procedure in 109 patients (77 men) with angina, 42 of whom had unstable angina. Of the 109 patients, 86 had a stent inserted (21 as a primary stent), nine had PTCA, eight had RA and six intracoronary brachytherapy. Using the manufacturers' recommended cut-offs ± CK-MB 4 g/L, cTnI and cTnT 0´1 g/L ± ®ve patients were excluded from further analysis as all three markers were raised pre-procedure. Post procedure all three markers were in agreement for 68 patients (44 all normal, 24 all raised). Overall, CK-MB was raised in 28 patients, cTnT in 38 and cTnI in 58. In 19 patients CK-MB and cTnT were normal, but cTnI was raised (15 between 0´11 and 0´30 g/L). cTnI was the most sensitive indicator of minor myocardial damage, but at the recommended cut-off of 0´1 g/L may be overly sensitive. We await the results of our follow-up study to determine the clinical implications of these small rises in cTnI.
INTRODUCTION
Biochemical markers of cardiac cell damage are well established tools for the identi®cation of acute myocardial infarction (AMI). 1, 2 These markers include the enzyme creatine kinase, in particular its more cardiac-speci®c isoform creatine kinase MB isoenzyme (CK-MB), and the structural molecules that form the troponin complex. In contrast to CK and CK-MB molecules, the troponins have cardiac and skeletal isoforms which are encoded by separate genes and possess unique amino acid sequences. 3, 4 The cardiac troponins are not usually detectable within the circulation. For example, a study of 112 healthy adults demonstrated that troponin T was less than 0´1 g/L in all subjects. 5 Any ischaemic cardiac event that leads to myocardial cell damage or necrosis can cause the release of these molecules into the circulation. The high speci®city of the cardiac troponins for minor myocardial damage has led to their use in assessing prognosis in patients with unstable angina, in whom a detectable cardiac troponin I (cTnI) or cardiac troponin T (cTnT) concentration is associated with a high incidence of need for revascularization or of progression to AMI and cardiac death. 6±8 Patients with angina may, as part of their treatment, undergo percutaneous coronary intervention procedures such as percutaneous transluminal coronary angioplasty (PTCA), stent insertion and rotational atherectomy. These revascularization procedures aim to relieve narrowings or obstructions in coronary vessels and allow free blood¯ow to the myocardial tissue. Several studies have shown that asymptomatic rises in cardiac markers can occur during the hours following successful revascularization procedures, and that these rises are associated with an increased risk of an adverse clinical outcome. 9±13 In a recent study, which monitored CK and CK-MB elevations following intervention, 13 there was a clear association between increases in the concentrations of these enzymes and short-term adverse clinical outcome, including increased risk of death, reinfarction and emergency revascularization. Other studies have demonstrated rises in cTnT occurring 18±24 h post-intervention, 11 with a mean concentration of 0´61 0´80 mg/L being attained during that period (upper limit of normal for cTnT quoted as 0´1 mg/L). During follow-up it was observed that patients who had abnormal cTnT values were more likely to undergo repeat revascularization procedures than were those with normal cTnT values.
This evidence of an association between cardiac damage at the time of intervention, as demonstrated by rises in cardiac markers, and patient outcome is potentially very useful. At present, a proportion of patients who have undergone cardiac intervention need further revascularization or hospitalization at a later date, despite having received an apparently successful procedure with a good angiographic result. It would be helpful to be able to identify at the time of the index procedure this high-risk population which might have subsequent cardiac events.
The ®eld of cardiac intervention is rapidly expanding, with new techniques being developed and implemented within the clinical setting. From a technical point of view it would be useful to have an objective method for comparing the different revascularization procedures in terms of the degree of cellular damage they cause and the potential long-term consequences of such injury.
To investigate the use of cardiac markers as indicators of cellular injury caused by cardiac intervention, a sensitive and speci®c marker of minor myocardial damage must be identi®ed. The data presented here are the results of a pilot study designed to assess the performance of three cardiac markers, CK-MB, cTnT and cTnI, measured in patients undergoing a variety of cardiac intervention procedures, in order to identify the most sensitive marker. The question of how myocardial damage at the time of intervention relates to patient prognosis and outcome is the subject of a long-term follow-up study.
MATERIALS AND METHODS
The study population consisted of 109 patients undergoing treatment for angina with percutaneous coronary interventional procedures. The patient demographic data are presented in Table 1 . Forty-two of the patients presented with unstable angina. Of the total population, 15 patients received PTCA, 86 had a stent inserted (21 as a primary stent) and eight underwent rotational atherectomy. All patients gave informed consent as approved by the King's Healthcare Research Ethics Committee.
Coronary artery revascularization procedures
All patients received antiplatelet treatment with aspirin at least 1 day before the revascularization procedure.
PTCA and stent insertion
These procedures were carried out using the right femoral artery approach. An 8 F sheath was introduced under local anaesthetic and cTnT, cTnI and CK-MB to detect minor cardiac damage 765
Ann Clin Biochem 2000: 37 10 000 units of heparin were administered intravascularly. The coronary vessel was intubated with a catheter and a guidewire was inserted and manipulated across the target lesion. A balloon angioplasty catheter was advanced across the guidewire, centred at the site of stenosis and in¯ated over a period of seconds or minutes to pressures of 4±20 atmospheres. The duration of balloon in¯ation was limited primarily by the development of ischaemic electrocardiogram changes or symptoms of chest discomfort caused by the interruption of distal coronary blood¯ow. The coronary artery was then re-examined angiographically to assess the result of the angioplasty. If the result was suboptimal either the patient received further balloon in¯ation or a coronary stent was inserted. Coronary stents act as a metal support or`scaffold' to maintain the stretch of a diseased coronary segment. They may be inserted as a primary procedure or following PTCA.
Rotational atherectomy
This procedure was performed using the same vascular approach as the PTCA procedures. Rotational atherectomy uses a high-speed rotating diamond-encrusted burr that selectively ablates ®brocalci®c plaque from within the coronary artery. Normal elastic tissue is de¯ected away from the burr, which leaves a near-circular lumen as it passes through the atherosclerotic plaque. Instead of inducing plaque rupture and arterial stretching, as does balloon in¯ation, rotational atherectomy causes the plaque to be pulverized into minute particles which are approximately the same size as red blood cells. These particles are continuallȳ ushed`downstream', away from the lesion site, with a cocktail of heparin, nitrates and calcium antagonists infused through the rotablator system. This technique is therefore suitable for treating highly calci®ed coronary lesions which may be resistant to PTCA intervention.
Samples
Blood samples for CK-MB, cTnT and cTnI analysis were taken immediately before and at 6, 14 and 24 h post-procedure. Samples were centrifuged at 2000 g for 10 min and the serum was separated and stored at 20 C prior to analysis.
Analytical techniques
CK-MB and cTnI were measured using an Immuno-1 immunoassay analyser (Bayer, Newbury, UK) using sandwich enzyme-labelled assays with magnetic separation. The detection limit for both assays was 0´1 mg/L and the analytical range was 0´1±300 mg/L for the CK-MB assay and 0´1±200 mg/L for the cTnI assay. For the CK-MB assay the capture and detection antibodies were mouse monoclonals. For cTnI the capture antibody was a mouse monoclonal and the detection antibody was a goat polyclonal. Both antibodies in the cTnI assay were directed towards epitopes in the centre of the cTnI molecule. In both assays the detection antibodies were labelled with alkaline phosphatase and the addition of a substrate resulted in a colour change which was directly proportional to the analyte concentration. Inter-assay coef®cients of variation (CVs) were: CK-MB 6´1% at 4´6 mg/L and cTnI 6% at 0´2 mg/L.
cTnT was measured using a semiautomated ES300 analyser (Roche Diagnostics, Lewes, UK), which uses a second-generation cTnT assay based on ELISA technology with streptavidin-coded tubes as the means of separation. Both capture and detection antibodies were mouse monoclonals. Horseradish peroxidase was attached to the detection antibody. The detection limit for this assay was 0´02 mg/L with an analytical range of 0´02±15 mg/L. The interassay CV for cTnT was 6% at 0´27 mg/L.
The manufacturers' stated cut-off values for CK-MB, cTnI and cTnT were 4 mg/L, 0´1 mg/L and 0´1 mg/L, respectively.
RESULTS
Of the 109 patients recruited to the study, ®ve were found to have all three markers raised above the respective cut-off limits on the preprocedure sample. These patients (who all subsequently received stent insertion) were excluded from the data analysis on the grounds that they had biochemical evidence of ongoing ischaemic damage which was not related to their cardiac intervention.
The median value of each analyte at each time point is shown in Table 2 , together with the lower and upper quartile values. There was an increase in the median value for each analyte over the 24-h period and, more noticeably, the interquartile ranges increased considerably over this time, indicating that there was a widening spread of results with more positives being attained as the 24 h proceeded.
The number of positive values attained for each analyte over the 24-h monitoring period is shown in Table 3 . In 68 cases (65%) all three markers were in agreement, with 44 cases (42%) showing no rise in any of the markers and 24 cases (23%) showing a rise in all three. Of the remaining 36 cases, 19 had positive cTnI values during the 24-h period with no concurrent rises in CK-MB or cTnT. There were no cases of isolated raised CK-MB and only one case in which cTnT became raised in the absence of CK-MB or cTnI rises.
DISCUSSION
We have measured changes in CK-MB, cTnT and cTnI over a period of 24 h post procedure in a group of patients undergoing percutaneous coronary revascularization, with a view to determining the most sensitive marker of minor myocardial damage. In 42% of patients all three cardiac markers remained negative over the 24 h following intervention. Of the remaining 58% of patients the majority showed rises in cTnI, with 19 cases (18%) demonstrating a rise in cTnI without changes being observed in cTnT or CK-MB. However, in 15 of these 19 cases the rises in cTnI were very small, with concentrations of between 0´11 and 0´3 mg/L being observed. The clinical signi®cance of these small rises is yet to be established, but we hope to determine this in our long-term follow-up study, where we will use cTnI as the most sensitive marker to monitor myocardial damage post intervention in a larger cohort of patients undergoing a variety of procedures.
The results of our investigation are in agreement with other studies that report rises in cardiac markers following intervention. 9±13 However, within these reports there is considerable variation in the times selected for blood sampling post intervention. These range from a period spanning 24 h 11 to up to 4 days post procedure. 12 Johansen et al. 12 chose to take samples for analysis at 4 days post procedure on the grounds that their chosen analyte, cTnT, is known to have a biphasic release pattern. 14 The ®rst phase occurs over 24 h and may re¯ect cell necrosis caused by ischaemia, with a later peak occurring if successful reperfusion of the affected area is achieved. 5 We elected to monitor the cardiac markers over 24 h for two reasons. coronary artery surgery, indicated that the peak release of cTnT occurred at 6 h post bypass. 15 This peak was not prolonged and was therefore likely to be due to the release of cytosolic cTnT, re¯ecting reversible ischaemia as opposed to tissue necrosis. We expected a similar degree of myocardial injury to occur following percutaneous coronary intervention. A second, more pragmatic, reason for choosing a period of 24 h post intervention is that, provided there are no clinical reasons for detaining them, patients who have undergone these procedures within our Cardiology Department are discharged after 24 h. The issue of which cut-off values to use in the assessment of positivity and negativity in cardiac markers is a dif®cult one. We measured cTnT using the Roche ES300 system, for which a cutoff value of 0´1 mg/L is recommended. However, the introduction of the new Roche Elecsys analyser has reduced the cTnT cut-off value to 0´04 mg/L. It is expected that by adopting this lower cut-off there would be little to choose between the sensitivity of cTnI and that of cTnT. Indeed, several reports claim comparable results between cTnI and cTnT when assessing their respective sensitivities for the detection of myocardial damage in unstable angina 16,17 and in patients with AMI. 18 Neither cTnT nor cTnI is the perfect marker for cardiac damage. In the past concerns have been raised regarding the speci®city of cTnT, with reports showing that it could be detected in patients with chronic renal failure and that it appeared to be expressed in regenerating skeletal muscle. 19 However, recent studies have demonstrated that elevated cTnT concentrations in patients on haemodialysis are evidence for the presence of a degree of myocardial injury, and are associated with a poor outcome. 20 In contrast, the problem of standardization of cTnI assays is notorious 21±23 and, because of the number of manufacturers involved in producing such assays, it is likely to remain so for the present. cTnI is a more hydrophobic molecule than cTnT and it is released and carried in the serum as a complex with troponin C, rather than as a free entity. 24,25 A variety of methods are available that use antibodies raised to different regions of the molecule. 26 However, there is considerable variation in the stability of the various regions of the cTnI molecule. The N-and C-terminal regions in particular are susceptible to degradation by proteolytic action, 27,28 whereas the central region is more stable and probably protected from proteolysis by the binding of troponin C to this region. Hence, assays that use antibodies directed at the central region of the protein will detect intact cTnI and fragments which have lost the terminal regions, whereas if the target antibodies overlap the region of fragmentation some fragments of the molecule may not be detected. Therefore, assays in which the antibodies are directed towards the terminal ends of cTnI may be underestimating the concentration of total cTnI in the serum. Determination of the secondary structure of cTnI by Ferrieres et al. 29 has revealed that it is likely to be an extended structure with ®ve a-helical regions, and that most of the molecule is antigenic. Katrukha et al. 27 suggest that the development of assays using antibodies directed at the central regions of the cTnI molecule will provide a more sensitive and reliable method of detecting cTnI, as these assays will be more resistant to proteolysis. The assay used to measure cTnI in this study uses antibodies directed towards sites within the central region of cTnI, and hence is likely to be less susceptible to proteolytic effects than are other assays. The assay also has an equimolar response to complexed and intact cTnI. The long-term goal for manufacturers of cTnI assays must be the development of a cTnI reference material which can be used to standardize the different methods. Until this is achieved, it remains dif®cult to compare directly the results from studies that use different cTnI methods.
CONCLUSION
This study supports the ®ndings of other research workers that percutaneous coronary revascularization may be associated with variable degrees of myocardial cell damage, as demonstrated by post-procedural rises in cardiac markers. We found elevations of cardiac markers in up to 56% of patients undergoing coronary revascularization procedures, and cTnI was found to be the most sensitive marker for the detection of minor myocardial injury in this setting. We anticipate that our follow-up study will provide information regarding long-term clinical outcome in these patients.
